Sarcopenia represents an independent adverse event in metastatic castration-resistant prostate cancer (mCRPC) patients candidates to Radium-223 therapy

Autor:	D'Amico, F., Lai, R., Donegani, M., Miceli, A., Raffa, S., Campi, C., Delucchi, C., Schenone, D., Rebuzzi, S., Fornarini, G., Piana, M., Marini, C., Morbelli, S., Sambuceti, G., Bauckneht, M.
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Sarcopenia prostate cancer
Zdroj:	European journal of nuclear medicine and molecular imaging 48 (2021): S234–S235. doi:10.1007/s00259-021-05547-1 info:cnr-pdr/source/autori:D'Amico, F.; Lai, R.; Donegani, M.; Miceli, A.; Raffa, S.; Campi, C.; Delucchi, C.; Schenone, D.; Rebuzzi, S.; Fornarini, G.; Piana, M.; Marini, C.; Morbelli, S.; Sambuceti, G.; Bauckneht, M./titolo:Sarcopenia represents an independent adverse event in metastatic castration-resistant prostate cancer (mCRPC) patients candidates to Radium-223 therapy/doi:10.1007%2Fs00259-021-05547-1/rivista:European journal of nuclear medicine and molecular imaging (Print)/anno:2021/pagina_da:S234/pagina_a:S235/intervallo_pagine:S234–S235/volume:48
DOI:	10.1007/s00259-021-05547-1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=cnr_________::6f5fa1ff94cac2e3022d8d385507aef8 https://publications.cnr.it/doc/462639 Zobrazit plný text záznamu